As a follow up In case this hasnt been posted.
Post# of 148277
Quote
"Just last week, data from a U.S. government-led, placebo-controlled, double-blinded study showed remdesivir cut death rates by 70% in patients receiving low-flow oxygen and cut recovery time by 86% in severe patients."
Source:
https://www.fiercepharma.com/special-report/m...a-brainard
How can this be true based on all of the real data out there.
Sounds like someone is bending the rules to line Gilead's profits and shareholders stock price.